May 235 min readMedNews: Clinical-stage pharmaceutical company Inhibikase Therapeutics (Nasdaq: IKT) raises $4 millionThe company's multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract
